Enhanced Type 1 Interferon Signature in Axial Spondyloarthritis Patients Unresponsive to Secukinumab Treatment
The increased frequency of IL-17A-producing cells in SEC-NR patients suggests a larger inflammatory burden than SEC-R patients. With treatment, SEC-NR patients have a more pronounced type 1 IFN signature than SEC-R patients, suggesting a mechanism contributing to this larger inflammatory burden. The results point toward more immune heterogeneity in axSpA than has been recognized and highlights the need for precision therapeutics in this disease.
Authors
- Melissa Lim (ORCID: https://orcid.org/0000-0002-6956-8687)
- Fataneh Tavasolian (ORCID: https://orcid.org/0000-0002-3572-1954)
- Robert D. Inman (ORCID: https://orcid.org/0000-0002-4750-1422)
- Nigil Haroon (ORCID: https://orcid.org/0000-0003-3210-4771)
- Michael Tang (ORCID: https://orcid.org/0000-0003-0131-6659)
- Sinead Maguire (ORCID: https://orcid.org/0000-0002-1982-8962)
- Zoya Qaiyum (ORCID: https://orcid.org/0000-0002-1698-0360)
- Sarah Q. Crome (ORCID: https://orcid.org/0000-0001-5117-7453)
- Enoch Yau
- Addison Pacheco (ORCID: https://orcid.org/0000-0003-4684-2775)
- Adam Bridger
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- Toronto Western Hospital (CA)
- Toronto General Hospital (CA)
- Arthritis Society (CA)
- Zero to Three (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1002/art.42974
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Arthritis Society
- Novartis Pharmaceuticals Canada